

Original Article

Inhibition of Glioma Cell Line A-172 MMP Activity and Cell Invasion In Vitro by a Nutrient Mixture

M. Waheed Roomi, Vadim Ivanov, Tatiana Kalinovsky, Aleksandra Niedzwiecki, and Matthias Rath

Dr. Rath Research Institute, Oncology Division, 1260 Memorex Drive, Santa Clara, CA 95050

Abstract

Standard multimodality therapy of gliomas is associated with poor patient survival and significant toxicity. Abnormal expression of matrix metalloproteinases is associated with tumor growth and invasion. Based on reported antitumor properties, we investigated the effect of a combination of natural compounds (NM), primarily composed of lysine, proline, ascorbic acid, and green tea extract in vitro on glioma cell line A-172, by measuring MMP secretion, invasion through Matrigel, and cell proliferation. Glioma cells A-172 (ATCC) were grown in modified Dulbecco's Eagle medium with 10% fetal bovine serum and antibiotics and treated with NM at 0, 10, 50, 100, 500, and 1000 µg/mL concentration in triplicate at each dose. Cell proliferation was assayed by MTT, MMP secretion by zymography, invasion through Matrigel, and morphology by H&E staining. Zymography showed one band corresponding to MMP-2, which was inhibited by NM in a dose-dependent fashion, with virtual total inhibition at 500-µg/mL concentration. Invasion through Matrigel was completely inhibited at 1000 µg/mL NM. NM was not toxic to glioma cell line A-172 at lower concentrations and exhibited toxicity of 50% over the control at 1000 µg/mL. NM significantly inhibited MMP secretion and invasion-important parameters for cancer prevention, suggesting a possible therapeutic role.

Key Words: Glioma; MMPs; Matrigel invasion; nutrients.

Introduction

Approximately 18,820 new cases and 12,820 deaths from brain and other nervous system tumors are estimated in the United States for 2006, accounting for 2.4% of all cancer deaths. Brain tumors are the major cause of cancer-related death in patients under 15 yr of age, and cancer remains the leading medical cause of death among children in the United States (1).

Roughly 40–50% of all pediatric CNS tumors are gliomas (2). Despite advances, pediatric patient outcome remains poor with long-term survival rates rang-

ing from 10% to 30% for supratentorial tumors (3) and less than 10% for diffuse brainstem gliomas (4). At recurrence, two-thirds of supratentorial tumors are local, 10% are isolated leptomeningeal failures, and the remaining fall under a combination of both (5).

Longer survival times have been achieved in patients with nondisseminated disease; however, adverse effects of surgical trauma and chemotherapeutic toxicity, such as subsequent malignancies have been widely reported (6–9). Specifically, anthracyclines and mediastinal radiation are associated with congestive heart failure and cardiac impairment (10,11). Both chemotherapy and radiation can result in pulmonary fibrosis, acute pulmonary toxicity, and restrictive lung disease (12–14). Toxic impairment of hepatic, renal, and gastrointestinal systems by

Received October 8, 2006; Accepted October 17, 2006.

Corresponding Author: Aleksandra Niedzwiecki, 1260 Memorex Drive, Santa Clara, CA 95050, Phone: 408-807-5564, Fax: 408-567-5030, E-mail: author@drath.com

chemotherapeutic agents and radiation has also been reported (15–17).

For the most part, cancer mortality is associated with distant metastases and consequent organ failure. In identifying the limitations and adverse effects of standard multimodality therapy, which fails to address metastasis, researchers have focused efforts on identifying various targets of cancer progression, including the inhibition of matrix metalloproteinases (MMPs). Key to metastasis and tumor growth is the degradation of components of the extracellular matrix (ECM) and tumor migration into nearby blood vessels. MMPs function to maintain balance between decomposition and restoration of tissue basic substance; however, when disturbances to this balance occur as with malignant disease, MMPs can support tumor cell invasion and metastasis by several mechanisms (18). MMPs are capable of facilitating tumor cell invasion by degrading ECM macromolecules such as collagens, laminins, and proteoglycans. MMPs can also modulate cell adhesion and expose hidden biologic activities by acting on ECM components (19–23). Studies have shown that increased expression of MMPs, especially MMP-2 and -9, correlate with poor patient survival and prognosis in a number of malignancies: breast cancer (24), pancreatic cancer (25), prostate cancer (26), lung cancer (27), esophageal cancer (28), stomach cancer (29), colon cancer (30), ovarian cancer (31), and brain cancer (32), among others.

Therapies designed to prevent metastatic disease through inhibition of MMP show great promise in the treatment of cancer, especially aggressive highly invasive malignancies, resistant to standard combined approaches of surgery, radiotherapy, chemotherapy, and immunotherapy. In recognition of this, Rath and Pauling postulated that nutrients such as lysine and ascorbic acid (vitamin C) could modulate tumor growth and expansion by preventing ECM proteolysis and stabilizing connective tissue via inhibition of MMPs (preserving matrix integrity) and strengthening of connective tissue surrounding cancer cells (tumor-encapsulating effect) (33). In previous studies, we demonstrated that the specific mixture of nutrients (NM), primarily composed of lysine, ascorbic acid, proline, and EGCG-enriched green tea extract, inhibited tumor growth, tissue invasion, angiogenesis, and MMP secretion in both animal model (34) and cell culture experiments (35). In the current study, we

investigated the anti-tumor potential of NM in vitro on glioma cell line A-172, by measuring MMP secretion, cell invasion through Matrigel, and cell proliferation.

Materials and Methods

Cell Culture

Glioma cells A-172 obtained from ATCC (American Type Culture Collection, Rockville, MD), were grown in Dulbecco's Eagle medium, supplemented with 10% fetal bovine serum, penicillin (100 U/mL) and streptomycin (100 mg/mL) in 24-well tissue culture plates (Costar, Cambridge, MA). Cells were incubated with 1 mL of media at 37°C in a tissue culture incubator equilibrated with 95% air and 5% CO₂. At near confluence, the cells were treated with the nutrient mixture (NM), dissolved in media and tested at 0, 10, 50, 100, 500, and 1000 µg/mL in triplicate at each dose. The plates were then returned to the incubator.

MTT Assay

Cell proliferation was evaluated by MTT assay, a colorimetric assay based on the ability of viable cells to reduce a soluble yellow tetrazolium salt [3-(4,5-dimethylthiazol-2-yl) 2,5-diphenyl tetrazolium bromide] (MTT) to a blue formazan crystal by mitochondrial succinate dehydrogenase activity of viable cells. This test is a good index of mitochondrial activity and thus of cell viability. After 24 h incubation, the cells were washed with phosphate-buffered saline (PBS) and 500 µL of MTT (Sigma cat. no. M-2128) 0.5 mg/mL in media was added to each well. After MTT addition (0.5 mg/mL) the plates were covered and returned to the 37°C incubator for 2 h, the optimal time for formazan product formation. Following incubation, the supernatant was carefully removed from the wells, the formazan product was dissolved in 1 mL DMSO, and absorbance was measured at 570 nm in Bio Spec 1601, Shimadzu spectrometer. The OD₅₇₀ of the DMSO solution in each well was considered to be proportional to the number of cells. The OD₅₇₀ of the control (treatment without supplement) was considered 100%.

Gelatinase Zymography

MMP secretion in conditioned media was determined by gelatinase zymography. Gelatinase zymog-

raphy was performed in 10% Novex precast SDS-polyacrylamide gel (Invitrogen Corporation) in the presence of 0.1% gelatin under non-reduced conditions. Culture media (20 μ L) mixed with sample buffer was loaded and SDS-PAGE was performed with Tris glycine SDS buffer as described by the manufacturer (Novex). Samples were not boiled before electrophoresis. Following electrophoresis the gels were washed twice in 2.5% Triton X-100 for 30 min at room temperature to remove SDS. The gels were then incubated at 37² C overnight in substrate buffer containing 50 mM Tris-HCl and 10 mM CaCl₂ at pH 8.0 and stained with 0.5% Coomassie Blue R250 in 50% methanol and 10% glacial acetic acid for 30 min and destained. Protein standards were run concurrently and approximate molecular weights were determined by plotting the relative mobilities of known proteins.

Gelatinase zymograms were scanned using CanoScan 9950F Canon scanner at 1200 dpi. The intensity of the bands was evaluated using a pixel-based densitometer program Un-Scan-It, Version 5.1, 32-bit, by Silk Scientific Corporation (P.O. Box 533, Orem, UT 84059, USA), at a resolution of 1 Scanner Unit (1/100 of an inch for an image that was scanned at 100 dpi), and expressed as a percentage of control. The R^2 value (0 to 1) on graphs represents how well the line of best fit falls on the dependent data, with $R^2 = 1.0$ being the best possible fit.

Matrigel Invasion Studies

Invasion studies were conducted using Matrigel (Becton Dickinson) inserts in 24-well plates. Suspended in medium, human glioma cells were supplemented with nutrients, as specified in the design of the experiment and seeded on the insert in the well. Thus both the medium on the insert and in the well contained the same supplements. The plates with the inserts were then incubated in a culture incubator equilibrated with 95% air and 5% CO₂ for 24 h. After incubation, the media from the wells were withdrawn. The cells on the upper surface of the inserts were gently scrubbed away with cotton swabs. The cells that had penetrated the Matrigel membrane and migrated onto the lower surface of the Matrigel were stained with hematoxylin and eosin and visually counted under the microscope.

Morphology

Morphology of cells cultured for 24 h in test concentrations of NM were evaluated by H&E staining and observed and photographed by microscopy.

Composition of Nutrient Mixture (NM)

Stock solution of the nutrient mixture prepared for testing was composed of the following in the ratio indicated: Vitamin C (as ascorbic acid and as Mg, Ca, and palmitate ascorbate) 700 mg; L-lysine 1000 mg; L-proline 750 mg; L-arginine 500 mg; N-acetyl cysteine 200 mg; standardized green tea extract 1000 mg [green tea extract derived from green tea leaves was obtained from US Pharma Lab; the certificate of analysis indicates the following characteristics: total polyphenol 80%, catechins 60%, epigallocatechin gallate (EGCG) 35%, and caffeine 1.0%]; selenium 30 μ g; copper 2 mg; manganese 1 mg.

Statistical Analysis

The results were expressed as means \pm SD for the groups. Data was analyzed by independent sample "t" test.

Results

Cell Proliferation Study

NM was not toxic to glioma cell line A-172 at lower concentrations and exhibited toxicity of 50% over the control at 1000 μ g/mL, $p = 0.003$, as shown in Fig. 1.

Gelatinase Zymography Study

Zymography demonstrated only one band corresponding to MMP-2. NM inhibited the secretion of MMP-2 in a dose-dependent fashion, with virtual inhibition at 500- μ g/mL concentration, as shown in Fig. 2A. Densitometry analysis on relative activity of MMP-2 showed 21% inhibition at 50 μ g/mL and 48% at 500 μ g/mL and 99% at 1000 μ g/mL, with $R^2 = 0.8514$ (Fig. 2B).

Invasion Study

The nutrient mixture (NM) significantly reduced the invasion of glioma cells through Matrigel in a dose-dependent fashion, with 93% inhibition at 500 μ g/mL ($p = 0.003$) and 100% at 1000 μ g/mL NM ($p = 0.002$), as shown in Figs. 3A–E.




Fig. 1. Effect of the nutrient mixture (NM) on growth of glioma cells: 24 h MTT assay. NM was not toxic to glioma cell line A-172 at lower concentrations and exhibited toxicity of 50% over the control at 1000 $\mu\text{g}/\text{mL}$, $p = 0.003$




Fig. 2. Effect of the nutrient mixture (NM) on MMP-2 secretion by glioma cells. (A) Zymogram, Legend 1, Markers; 2 Control; 3–7 NM 10, 50, 100, 500, 1000 $\mu\text{g}/\text{mL}$. Zymography demonstrated only one band corresponding to MMP-2. NM inhibited the secretion of MMP-2 in a dose-dependent fashion, with virtual inhibition at 500- $\mu\text{g}/\text{mL}$ concentration. (B) Densitometry analysis. Effect of nutrient mixture (NM) on relative activity of MMP-2 in human glioblastoma (A172).

Morphology Study (Hematoxylin and Eosin Staining)

H&E staining showed no morphological changes even at higher levels of NM (Figs. 4A–E).

Discussion

Glioblastoma demonstrates rapid progression and is highly resistant to standard treatment, resulting in a particularly poor prognosis in patients. Glioma-




Fig. 3. Effect of the nutrient mixture (NM) on glioma cell Matrigel invasion. NM significantly reduced the invasion of glioma cells through Matrigel in a dose-dependent fashion, with 93% inhibition at 500 $\mu\text{g/mL}$ ($p = 0.003$) and 100% at 1000 $\mu\text{g/mL}$ NM ($p = 0.002$). (A) Control; (B) NM 50 $\mu\text{g/mL}$; (C) NM 100 $\mu\text{g/mL}$; (D) 500 $\mu\text{g/mL}$; (E) 1000 $\mu\text{g/mL}$.

blastoma is distinct from other cancer types by exhibiting profoundly vascularized tumors, necrosis, and microvascular hyperplasia. Pseudopalisades and microvascular hyperplasia are indicative of aggressive growth and are instrumental in malignant progression (36). Pseudopalisading cells also express high levels of vascular endothelial growth factor (VEGF), which promote endothelial proliferation and angiogenesis. The nutrient mixture (NM) tested was formulated based on targeting different physiological processes involved in cancer progression and metastasis. Selenium, a component of NM, has been shown to prevent migration of endothelial cells through the

ECM (37). Green tea extract, another major component in NM, has been shown to control angiogenesis by inhibition of angiogenic factors such as VEGF (38). In addition, we recently showed that NM caused a significant ($p < 0.05$) reduction in bFGF-induced angiogenesis in a chorioallantoic membrane (CAM) assay in chick embryos, as well as decreased human osteosarcoma U2OS cell expression of VEGF, angiopoietin-2, bFGF, PDGF, and TGFbeta-1 (39).

Additionally, increased MMP levels are associated with poor prognosis in glioblastoma patients. MMP-2 can cleave laminin 5 $\gamma 2$ and release proteolytic fragments which are capable of leading to




Fig. 4. Effect of NM on glioma cell morphology (H&E staining). (A) Control; (B) NM 50 µg/mL; (C) NM 100 µg/mL; (D) 500 µg/mL; (E) 1000 µg/mL. H&E staining showed no morphological changes even at higher levels of NM.

tumor cell invasion and prevention of tumor cell apoptosis via epidermal growth factor receptor (40). In this study, NM demonstrated significant inhibition of human malignant glioma cell line A-172 cell invasive parameters by complete inhibition of MMP-2 secretion at 500 µg/mL. Invasion through Matrigel was completely inhibited at 1000 µg/mL concentration NM. While a mechanistic study was not undertaken, researchers have shown various antitumoral properties of the nutrients comprising NM: selenium can block MMP expression and tumor invasion (37); ascorbic acid can inhibit cell division and growth through production of hydrogen peroxide (41); green tea extract can inhibit metastasis; and nitric oxide (arginine is a precursor of nitric oxide) can induce apoptosis (42).

Rath and Pauling suggested targeting plasmin-mediated mechanisms with the use of nutritional components, such as lysine and lysine analogs (33). ECM integrity is dependent on adequate collagen formation and stability. Collagen stability is supported by lysine (33) and also by N-acetyl cysteine through its inhibitory effect on MMP-9 activity (43) and invasive activities of tumor cells (44). Furthermore, ascorbic acid and both lysine and proline are necessary for the formation and optimum

structure of collagen fibers. Manganese and copper are also essential cofactors in collagen formation process. We postulated that metabolic effects of a combination of ascorbic acid, lysine, proline, green tea extract, arginine, N-acetyl cysteine, selenium, copper, and manganese would result from their synergy. In an earlier study, we found that a combination of ascorbic acid, lysine, and proline used with EGCG enhanced the anti-invasive activity of 20 µg/mL EGCG to that of 50 µg/mL (45).

While animal and clinical studies are necessary to better determine the efficacy of the formulation of lysine, proline, arginine, ascorbic acid, and green tea extract in the prevention and treatment of glioma, the results of this study suggest that NM is a promising candidate for therapeutic use by inhibiting cell growth, MMP secretion, and invasion in glioma cell line A-172.

References

1. Khatua S, Jalali R. Recent advances in the treatment of childhood brain tumors. *Pediatr Hematol Oncol* 2005; **22**(5):361–371.
2. Pollack IF: Brain tumors in children. *N Engl J Med* 1994; **331**:1500–1507.

3. Sposto R, et al. The effectiveness of chemotherapy for treatment of high grade astrocytoma in children: results of a randomized trial: a report from the Childrens Cancer Study Group. *J Neurooncol* 1989; **7**:165–177.
4. Packer RJ, et al. Hyperfractionated radiation therapy (72 Gy) for children with brain stem gliomas: a Childrens Cancer Group Phase I/II trial. *Cancer* 1993; **72**:1414–1421.
5. Heideman RL, et al. Supratentorial malignant gliomas in childhood: a single institution perspective. *Cancer* 1997; **80**(3):497–504.
6. Robison LL, Mertens AC. Second tumors after treatment of childhood malignancies. *Hematol Oncol Clin North Am* 1993; **7**:401–415.
7. Smith MB, et al. Forty-year experience with second malignancies after treatment of childhood cancer: Analysis of outcome following the development of the second malignancy. *J Pediatr Surg* 1993; **28**:1342–1348.
8. Bhatia S, et al. Breast cancer and other second neoplasms after childhood Hodgkin's disease. *N Engl J Med* 1996; **334**(12):745–751.
9. Pratt CB, et al. Second malignant neoplasms occurring in survivors of osteosarcoma. *Cancer* 1997; **80**: 960–965.
10. Wong KY, Lampkin BC. Anthracycline toxicity. *Am J Pediatr Hematol Oncol* 1983; **5**: 93–97.
11. Hancock SL, Donaldson SS, Hoppe RT. Cardiac disease following treatment of Hodgkin's disease in children and adolescents. *J Clin Oncol* 1993; **11**:1208–1215.
12. O'Driscoll BR, et al. Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood. *N Engl J Med* 1990; **323**:378–382.
13. Morgan GW, Freeman AP, McLean RG. Late cardiac, thyroid and pulmonary sequelae of mantle radiotherapy for Hodgkin's disease. *Int J Radiat Oncol Biol Phys* 1985; **11**:1925–1931.
14. Jakacki RI, Schramm CM, Donahue BR, Haas F, Allen JC. Restrictive lung disease following treatment for malignant brain tumors: A potential late effect of craniospinal irradiation. *J Clin Oncol* 1995; **13**:1478–1485.
15. Green DM, Finklestein JZ, Norkool D'Angio GJ. Severe hepatic toxicity after treatment with single-dose dactinomycin and vincristine. *Cancer* 1988; **62**(2):270–273.
16. Johnson WW, Meadows DC. Urinary-bladder fibrosis and telangiectasia associated with long-term cyclophosphamide therapy. *N Engl J Med* 1971; **284**(6):290–294.
17. Wellwood JM, Jackson BT. The intestinal complications of radiotherapy. *Br J Surg* 1973; **60**: 814–818.
18. Engbring JA, Kleinman HK. The basement membrane matrix in malignancy. *J Pathol* 2003; **200**(4):465–470.
19. Hornebeck W, Maquart FX. Proteolyzed matrix as a template for the regulation of tumor progression. *Biomed Pharmacother* 2003; **57**(5–6):223–230.
20. Westermarck J, Kahari VM. Regulation of matrix metalloproteinase expression in tumor invasion. *FASEB J* 1999; **13**(8):781–792.
21. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. *Circ Res* 2003; **92**(8):827–839.
22. Leppa S, Saarto T, Vehmanen L, Blomqvist C, Elomaa I. A high serum matrix metalloproteinase-2 level is associated with an adverse prognosis in node-positive breast carcinoma. *Clin Cancer Res* 2004; **10**(3):1057–1063.
23. Sheen-Chen SM, Chen HS, Eng HL, Sheen CC, Chen WJ. Serum levels of matrix metalloproteinase 2 in patients with breast cancer. *Cancer Lett* 2001; **173**(1):79–82.
24. Talvensaaari-Mattila A, Paakko P, Hoyhtya M, Blanco-Sequeiros G, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 immunoreactive protein: a marker of aggressiveness in breast carcinoma. *Cancer* 1998; **83**:1153–1162.
25. Bramhall SR, Neoptolemos JR, Stamp GW, Lemoine NR. Imbalance of expression of matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs) in human pancreatic carcinoma. *J Pathol* 1997; **182**: 347–355.
26. Stearns M, Stearns ME. Evidence for increased activated metalloproteinase 2 (MMP-2a) expression associated with human prostate cancer progression. *Oncol Res* 1996; **8**: 69–75.
27. Kawano N, et al. Expression of gelatinase A, tissue inhibitor of metalloproteinases-2, matrilysin, and trypsin (ogen) in lung neoplasms: an immunohistochemical study. *Hum Pathol* 1997; **28**: 613–622.
28. Murray GI, et al. Matrix metalloproteinase-1 is associated with poor prognosis in esophageal cancer. *J Pathol* 1998; **185**: 256–261.
29. Sier CFM, et al. Tissue levels of matrix metalloproteinase MMP-2 and MMP-9 are related to the overall survival of patients with gastric carcinoma. *Br J Cancer* 1996; **74**: 413–417.
30. Murray GI, Duncan ME, O'Neil P, Melvin WT, Fothergill JE. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. *Nat Med* 1996; **2**: 461–462.
31. Young TN, et al. Characterization of gelatinases linked to extracellular matrix invasion in ovarian adenocarcinoma: purification of matrix metalloproteinase 2. *Gynecol Oncol* 1996; **62**:89–99.
32. Ozen O, et al. Expression of matrix metalloproteinases and their inhibitors in medulloblastomas and their prognostic relevance. *Clin Cancer Res* 2004; **10**(14):4746–4753.
33. Rath M, Pauling L. Plasmin-induced proteolysis and the role of apoprotein(a), lysine and synthetic analogs. *Orthomolecular Medicine* 1992; **7**: 17–23.
34. Roomi MW, Ivanov V, Kalinovsky T, Niedzwiecki A, Rath M. Modulation of *N*-methyl-*N*-nitrosourea induced mammary tumors in Sprague–Dawley rats by combination of lysine, proline, arginine, ascorbic acid and green tea extract. *Breast Cancer Research* 2005; **7**: R291–R295.
35. Netke SP, Roomi MW, Ivanov V, Niedzwiecki A, Rath M. A specific combination of ascorbic acid, lysine, proline and epigallocatechin gallate inhibits proliferation and extracellular matrix invasion of various human cancer cell lines. *Research Communications in Pharmacology and Toxicology: Emerging Drugs* 2003; **2**:37–50.
36. Brat DJ, et al. Pseudopalisades in glioblastoma are hypoxic, express extracellular matrix proteases, and are formed by an actively migrating cell population. *Cancer Res* 2004; **64**(3): 920–927.
37. Yoon SO, Kim MM, Chung AS. Inhibitory effects of selenite on invasion of HT 1080 tumor cells. *J Biol Chem* 2001; **276**: 20085–20092.

38. Hare Y. *Green tea: health benefits and applications*, Marcel Dekker, New York, Basel, 2001.
39. Roomi MW, et al. Inhibitory effect of a mixture containing ascorbic acid, lysine, proline and green tea extract on critical parameters in angiogenesis. *Oncol Rep* 2005; **14**(4):807–815.
40. Giannelli G, Falk-Marzillier J, Schiraldi O, Stetler-Stevenson WG, Quaranta V. Induction of cell migration by matrix metalloprotease-2 cleavage of laminin-5. *Science* 1997; **277**:225–228.
41. Maramag C, Menon M, Balaji KC, Reddy PG, Laxmanan S. Effect of vitamin C on prostate cancer cells in vitro: effect on cell number, viability and DNA synthesis. *Prostate* 1997; **32**:188–195.
42. Cooke JP, Dzau VJ. Nitric oxide synthase: Role in the genesis of vascular disease. *Annu Rev Med* 1997; **48**: 489–509.
43. Kawakami S, Kageyama Y, Fujii Y, Kihara K, Oshima H. Inhibitory effects of N-acetyl cysteine on invasion and MMP 9 production of T24 human bladder cancer cells. *Anticancer Res* 2001; **21**: 213–219.
44. Morini M, et al. The role of the thiol N-acetyl cysteine in the prevention of tumor invasion and angiogenesis. *Int J Biol Markers* 1999; **4**: 268–271.
45. Roomi MW, Ivanov V, Kalinovsky T, Niedzwiecki A, Rath M. Synergistic antitumor effect of ascorbic acid, lysine, proline, and epigallocatechin gallate on human fibrosarcoma cells HT-1080. *Ann Cancer Res Ther* 2004; **12**: 148–157.